# Inspire Medical Systems Inc. (INSP) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Medical Devices & Supplies. Price $61.90, market value $1.8 billion.

## Valuation
- **P/E (trailing): 18.5×** (5-yr avg 62.4×, 3-yr avg 62.4×). Inspire Medical Systems Inc. trades at 18.5× trailing earnings, well below its own five-year average of 62.4×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 41.4×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.23**. A PEG of 0.23 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.0×**. Each dollar of revenue is priced at 2.0×.
- **Price / book: 2.3×**. The shares trade at 2.3× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 49.6×**. Enterprise value is 49.6× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 5.5%** (5-yr avg 0.8%). Free cash flow equals 5.5% of the market value, above its five-year average of 0.8%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 5.4%**. The inverse of the P/E: 5.4% of the price is earned each year.

## Profitability
- **Gross margin: 86.2%**. Inspire Medical Systems Inc. keeps 86.2% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 1.8%**. 1.8% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 15.9%**. 15.9% of each dollar of sales reaches the bottom line.
- **Return on equity: 18.6%**. 18.6% on shareholders' equity is solid.
- **Return on invested capital: 1.8%**. Return on all capital, debt included, is 1.8%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 11.1%**. Each dollar of assets produces 11.1% of profit.

## Growth
- **Revenue growth (1 yr): 13.6%** (3-yr 30.8%/yr, 5-yr 51.2%/yr). Revenue grew 13.6% over the last year, against 51.2% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 179.4%**. Earnings per share rose 179.4%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 216.6%/yr**. Free cash flow has compounded at 216.6% a year over three years.

## Financial health
- **Debt to equity: 0.03**. Debt is 0.03 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Inspire Medical Systems Inc. holds more cash than debt.
- **Current ratio: 6.08** (quick 6.08). Current assets cover the next year's liabilities 6.08 times.
- **Altman Z-score: 11.55**. A Z-score of 11.55 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Inspire Medical Systems Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (16 analysts). 16 analysts cover Inspire Medical Systems Inc.; the consensus is hold, with an average price target of $68.00 (+10% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -6.8%** (YTD -27.1%, 3-mo 28.7%). The shares are down 6.8% over twelve months including dividends.
- **From 52-week high: -57.9%** (59.1% above the low). Trading 58% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 1.11** (volatility 71%). Beta of 1.11 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=INSP · Page: https://foliofundamentals.com/stocks/insp

Not investment advice.